Mutations in the POLE-1 gene have been associated with high levels of neoantigens and tumor-infiltrating lymphocytes (TILs) in both the tumor and the tumor microenvironment (TME), suggesting POLE-1 mutational status in MSS metastatic colorectal cancer could be used to predict good response to ICI therapy [43]. Here, POLE is linked to metastatic colorectal cancer.